Designer Drugs: A New Look at Some Old (and Not So Old) Drugs

CMEO Webcast

Live Webcast: Wednesday, May 30, 2018
1:00 PM – 2:30 PM ET

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, May 30, 2019

Faculty

 

Mark S. Gold, MD (Moderator)
Chairman, Scientific Advisory Boards, RiverMend Health
Adjunct Professor of Psychiatry
Washington University School of Medicine
St. Louis, MO
17th University of Florida Distinguished Alumni Professor
Gainesville, FL

 

Jean Lud Cadet, MD
Senior Investigator (tenured)
Chief, Molecular Neuropsychiatry Research Branch
Chief, Molecular Neuropsychiatry Section
National Institutes of Health (NIH)/National Institute on Drug Abuse (NIDA) Intramural Research Program
Baltimore, MD

 

Charles Conway, MD
Professor of Psychiatry
Director, Treatment Resistant Depression and Neurostimulation Clinic
Director, Washington University Center for the Advancement of Research in ResistantMood and Affective Disorders (CARRMA)
Interventional Psychiatry Rotation Director
Washington University School of Medicine in St. Louis
St. Louis, MO

 

Gerard Sanacora, PhD, MD
Professor of Psychiatry, Yale School of Medicine
Director, Yale Depression Research Program
Ribicoff Research Facilities CMHC
Co-Director, Yale New Haven Hospital Interventional Psychiatry Service
New Haven, CT

Statement of Need

Join us for “Designer Drugs: A New Look at Some Old (and Not So Old) Drugs”, a panel discussion of new medical applications for common drugs of abuse. “Club Drugs” including nitrous oxide, ketamine, and MDMA are seeing increasing use by medical doctors as treatments for conditions like depression and PTSD, despite their not being approved for such use by the FDA. The panelists will talk about the abuse of these drugs and their research into new, legitimate uses.

Ketamine, widely used legally as an anesthetic and illegally in club settings is emerging up a potential new treatment for some types of depression. Dr. Gerard Sanacora – Professor of Psychiatry, Yale School of Medicine – will share his research on Ketamine and its uses in treating depression.

Dental patients are familiar with Nitrous Oxide, popularly known as “laughing gas”. Dr. Charles Conway – Professor of Psychiatry at Washington University School of Medicine in St. Louis – will discuss his research on Nitrous Oxide and the potential for it and other drugs of abuse to be used as treatments for depression.

Dr. Jean Lud Cadet – Chief of the Molecular Neuropsychiatry Research Branch and Associated Director for Diversity and Outreach at the Intramural Research Program (IRP) of NIDA – will discuss the potential use and abuse of MDMA, Methamphetamine, and other drugs for PTSD and other psychiatric diseases.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Increase awareness of new medical applications for common drugs of abuse including nitrous oxide, ketamine, and MDMA.
  • Explore the potential for use and abuse of MDMA, methamphetamine, and other drugs for PTSD and other psychiatric diseases.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Summarize potential new medical applications for common drugs of abuse including nitrous oxide, ketamine, and MDMA.
  • Describe the potential for use and abuse of MDMA, methamphetamine, and other drugs for PTSD and other psychiatric diseases.

Target Audience

Physicians, physician assistants, nurse practitioners, nurses and pharmacists.

Credit Information

CME Credit (Physicians):
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC and The Drug Enforcement Administration. CME Outfitters, LLC is accredited by the ACCME to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live actvity for a maximum of 1.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Nurse practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credits™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPECME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number: 0376-0000-18-017-L01-P

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST27395 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Gold has no disclosures to report.

Dr. Cadet has no disclosures to report.

Dr. Conway reports that he receives grants from the American Foundation for Suicide Prevention (Principal Investigator); Assurex Health, Inc. (Principal Investigator); Brain and Behavior Research Foundation (Co-Investigator); McDonnell Center for Systems Neuroscience (Co-Principal Investigator); National Institute of Mental Health (Principal Investigator); NeoSync, Inc. (Principal Investigator); Stanley Medical Research Institute (Co-Principal Investigator). He receives research support from Taylor Family Institute for Innovative Psychiatric Research; Barnes-Jewish Foundation; and Busch Foundation. He is a consultant for LivaNova.

Dr. Sanacora reports that he receives research support from Janssen Pharmaceuticals, Inc.; and Merck & Co., Inc. He is a consultant for Allergan; Alkermes; Axsome Therapeutics, Inc.; Biohaven Pharmaceuticals; Intra-Cellular Therapies; Janssen Pharmaceuticals, Inc.; Navitor Pharmaceuticals; Noven Pharmaceuticals, Inc.; Sage Pharmaceuticals; Sofinnova; and VistaGen Therapeutics, Inc. He is a stock shareholder (directly purchased) of Biohaven Pharmaceuticals. He receives other financial or material support for US patent US8778979 B2 with royalties paid from Biohaven Pharmaceuticals.

Jan Perez (planning committee) has no disclosures to report.

Disclosures have been obtained from CME Outfitters staff: No disclosures to report.

Unlabeled Use Disclosure

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.